Senior Vice President, Vaccines &
Anti-infectives Business Unit Head
Ms. Jenkins joined Emergent in 2018 and serves as head of the vaccines and anti-infectives business unit. She most recently served as chief commercial officer and U.S. business head, leading Commercial and Corporate Communications functions, for Aquinox Pharmaceuticals, a clinical-stage company with a lead drug candidate in the urology market. Before joining Aquinox, Ms. Jenkins was vice president of market access and a founding member of the commercial team for Relypsa Inc., a company that launched a product in 2015 to treat hyperkalemia, a life-threatening nephrology condition with significant unmet need. She has held innovative leadership roles spanning sales & marketing, market access, and business development at Actavis Inc., MedImmune LLC, and Pfizer Inc. Ms. Jenkins’ began her career as a scientist in the Bio-defense Division of Science Applications International Corporation, where her focus was working with Michigan Biologic Products Institute on regulatory aspects related to the investigational anthrax vaccine that later became BioThrax®, Emergent’s first product. BioThrax is now a core in-line product within her business unit.
Ms. Jenkins holds a Master of Science in Biotechnology & Biotech Business Enterprise from Johns Hopkins University and a Bachelor of Arts with Distinction in Psychology (Neuroscience)/Biology (Medical Microbiology) from Indiana University. She serves on the board of directors of Interstitial Cystitis Association and as a committee member of the Biotechnology Innovation Organization Policy, Access, and Reimbursement Committee.